UBS keeps Hold on Chugai Pharmaceutical stock at JPY 6,700 target

Published on 10/16/2026 at 10:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UBS kept a Hold rating on October 14, 2026 with a JPY 6,700 target. Chugai Pharmaceutical stock costs EUR 35.76 on October 16, 2026.

Analyst view and upcoming results

UBS maintained a Hold rating on October 14, 2026.
Second-quarter revenue reached JPY 341.58 billion, up from JPY 290.01 billion.
Chugai Pharmaceutical stock trades at EUR 35.76 at 10:06 a.m. CEST at Lang & Schwarz on October 16, 2026.

Chugai Pharmaceutical, JP3519400000, Illustration mit AI erstellt.

Chugai Pharmaceutical (ISIN JP3519400000) was assigned a Hold rating by UBS with a JPY 6,700 price target in a report dated October 14, 2026, according to Markets Insider. The report puts the analyst view against Chugai's product pipeline and the next quarterly update.

Three developments shape the story

On September 24, 2026, Chugai reported positive interim results from Roche's Phase III IMAGINATION study of sefaxersen in IgA nephropathy, with detailed data due at a medical meeting, according to Chugai Pharmaceutical. On September 28, 2026, the company said development of GYM329 for obesity would stop, while rights returned by Roche would support a possible spinal muscular atrophy program, as reported by JPX Market Explorer. UBS's October 14 rating was the latest of the three developments.

What does the JPY 6,700 target add?

The target sits beside stronger second-quarter operating figures. Chugai reported quarterly revenue of JPY 341.58 billion and net profit of JPY 116.33 billion for the quarter ended June 30, 2026, compared with revenue of JPY 290.01 billion and net profit of JPY 97.16 billion a year earlier, according to The Globe and Mail. The comparison gives the Hold rating a mixed foundation: recent earnings growth is visible, while pipeline execution remains material to the valuation.

Next date is October 27

Chugai's investor-relations calendar lists October 27, 2026, at 5:00 p.m. JST for third-quarter fiscal 2026 results and 6:00 p.m. JST for the related conference. The reporting period covers January through September 2026, according to the company's Chugai Pharmaceutical investor-relations page. That release is the next scheduled test of whether the revenue trend is carrying into the second half.

Stock price and market setting

On the Tokyo Stock Exchange, Chugai's 4519.T listing was last at JPY 6,353 on October 16, 2026, with a one-year range of JPY 5,974 to JPY 10,700. Its market capitalization was JPY 10.5 trillion at that quote, while the company is included in the Nikkei 225. The euro quotation provides a separate German investor view.

Chugai Pharmaceutical stock was trading at EUR 35.76 at Lang & Schwarz on October 16, 2026 at 10:06 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Chugai Pharmaceutical stock.